Endologix LLC reported 12-month results from the second of two studies of a fully percutaneous, transmural arterial bypass therapy for treating peripheral arterial disease. Presented at this month's annual Vascular Interventional Advances Conference in Las Vegas, the Detour-2 study revealed technical success in 100% of treated patients using the system which also surpassed a 30-day, major adverse event rate of just 7%.”